ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Sells $204,184.80 in Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CEO Jacob Chacko sold 24,660 shares of ORIC Pharmaceuticals stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $204,184.80. Following the transaction, the chief executive officer now owns 778,648 shares of the company's stock, valued at $6,447,205.44. This represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

ORIC Pharmaceuticals Price Performance

NASDAQ:ORIC traded up $0.01 during mid-day trading on Tuesday, reaching $8.25. The stock had a trading volume of 321,133 shares, compared to its average volume of 500,967. ORIC Pharmaceuticals, Inc. has a 12 month low of $6.33 and a 12 month high of $16.65. The stock has a market capitalization of $582.20 million, a PE ratio of -4.62 and a beta of 1.13. The stock has a 50-day simple moving average of $9.35 and a two-hundred day simple moving average of $9.37.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.01). Equities analysts expect that ORIC Pharmaceuticals, Inc. will post -1.84 EPS for the current year.

Wall Street Analyst Weigh In

ORIC has been the topic of a number of recent research reports. HC Wainwright reiterated a "buy" rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a research note on Monday, November 4th. Wedbush reaffirmed an "outperform" rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Tuesday, November 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Monday, September 23rd. Wells Fargo & Company began coverage on shares of ORIC Pharmaceuticals in a report on Thursday, October 31st. They set an "overweight" rating and a $20.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on ORIC Pharmaceuticals in a research note on Friday, September 6th. They issued a "buy" rating and a $20.00 price target for the company. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $18.29.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Franklin Resources Inc. boosted its stake in shares of ORIC Pharmaceuticals by 26.1% in the 3rd quarter. Franklin Resources Inc. now owns 950,459 shares of the company's stock valued at $9,067,000 after purchasing an additional 196,804 shares in the last quarter. Barclays PLC lifted its stake in ORIC Pharmaceuticals by 111.2% in the 3rd quarter. Barclays PLC now owns 107,261 shares of the company's stock valued at $1,100,000 after purchasing an additional 56,474 shares during the last quarter. Geode Capital Management LLC boosted its position in ORIC Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 1,273,513 shares of the company's stock valued at $13,056,000 after buying an additional 50,821 shares in the last quarter. M&T Bank Corp boosted its position in ORIC Pharmaceuticals by 19.2% in the third quarter. M&T Bank Corp now owns 85,137 shares of the company's stock valued at $873,000 after buying an additional 13,711 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of ORIC Pharmaceuticals by 42.0% during the third quarter. Wellington Management Group LLP now owns 174,388 shares of the company's stock worth $1,787,000 after buying an additional 51,565 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company's stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.